Go Pro
→ A $5 stock inside Kennedy Space Center? (From Freedom Financial) (Ad)tc pixel
NASDAQ:LTRN

Lantern Pharma Q2 2025 Earnings Report

Lantern Pharma logo
$2.80 +0.20 (+7.47%)
As of 02:34 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Lantern Pharma EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.53
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Lantern Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lantern Pharma Announcement Details

Quarter
Q2 2025
Date
8/13/2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Lantern Pharma's Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Lantern Pharma's Q2 2025 Press ReleasePress Release
(8-K)
Lantern Pharma's Q2 2025 Quarterly reportQuarterly report
(10-Q)

Lantern Pharma Earnings Headlines

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of ...
August 4 at 8:45 AM  |  finance.yahoo.comhttps://finance.yahoo.com/technology/ai/articles/lantern-pharma-nasdaq-ltrn-establishes-113000606.html
Lantern Pharma Spins Off Open-Medicine AI Platform
August 3 at 6:30 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/lantern-pharma-spins-off-open-medicine-ai-platform?utm_source=marketbeat.com&utm_medium=referral
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
August 4 at 1:00 AM  |  Stansberry Research (Ad)
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
August 3 at 7:30 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20260803318492/en/lantern-pharma-nasdaq-ltrn-establishes-open-medicine-ai-as-a-separate-company-to-commercialize-and-expand-its-multi-agent-ai-co-scientist-platform-for-the-transformation-of-medicine/
Lantern Pharma (NASDAQ:LTRN) Shares Down 3.5% - Here's Why
July 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30929720
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
July 28, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260728012034/en/Lantern-Pharma-to-Advance-EMA-Cleared-Phase-1b2-Trial-of-LP-184-Zirdafulven-in-Biomarker-Selected-Advanced-Bladder-Cancer/
See More Lantern Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lantern Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lantern Pharma and other key companies, straight to your email.

About Lantern Pharma

Lantern Pharma (NASDAQ:LTRN), Inc. is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need. Lead programs include LP-100, an alkylating agent advancing toward clinical evaluation in metastatic castration-resistant prostate cancer, and LP-184, a next-generation DNA-targeting compound in preclinical development for multiple solid tumors, including pancreatic and ovarian cancers. Lantern Pharma aims to streamline drug development timelines and reduce attrition rates by using AI-driven insights to inform preclinical and clinical strategies.

Lantern Pharma has established collaborations with institutions such as the National Cancer Institute’s Cancer Therapy Evaluation Program and academic partners to validate its platform and progress its candidates through regulatory pathways. The company’s approach blends computational analytics with traditional pharmacology, positioning Lantern to address the growing demand for precision oncology solutions. As it advances its pipeline, Lantern Pharma seeks to deliver new therapeutic options for patients and create long-term value through a data-driven development model.

View Lantern Pharma Profile
Earnings Tools